Class Ruling CR 2011/51
Date of effect: 1 July 2010

What this ruling is about: 1. This Ruling sets out the Commissioner's opinion on the way in which the relevant provision(s) identified below apply to the defined class of entities, who take part in the scheme to which this Ruling relates. Relevant provision(s) 2. The relevant provisions dealt with in this Ruling are: All subsequent legislative references are to the ITAA 1997, unless otherwise specified. Class of entities 3. The class of entities to which this Ruling applies is the shareholders in Sylvastate Limited (Sylvastate) who: Qualifications 4. The Commissioner makes this Ruling based on the precise arrangement identified in this Ruling. 5. The class of entities defined in this Ruling may rely on its contents provided the scheme actually carried out is carried out in accordance with the scheme described in paragraphs 9 to 28 of this Ruling. 6. If the scheme actually carried out is materially different from the scheme that is described in this Ruling, then: 7. This work is copyright. Apart from any use as permitted under the Copyright Act 1968 , no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to:

Class of entities or scheme: 3. The class of entities to which this Ruling applies is the shareholders in Sylvastate Limited (Sylvastate) who: | Qualifications: 4. The Commissioner makes this Ruling based on the precise arrangement identified in this Ruling. 5. The class of entities defined in this Ruling may rely on its contents provided the scheme actually carried out is carried out in accordance with the scheme described in paragraphs 9 to 28 of this Ruling. 6. If the scheme actually carried out is materially different from the scheme that is described in this Ruling, then: 7. This work is copyright. Apart from any use as permitted under the Copyright Act 1968 , no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to: 8. This Ruling applies from 1 July 2010 to 30 June 2011. The Ruling continues to apply after 30 June 2011 to all entities within the specified class who entered into the specified scheme during the term of the Ruling. However, this Ruling will not apply to taxpayers to the extent that it conflicts with the terms of a settlement of a dispute agreed to before the date of issue of this Ruling (see paragraphs 75 and 76 of Taxation Ruling TR 2006/10). 9. The following description of the scheme is based on information provided by the applicant. The following documents, or relevant parts of them form part of and are to be read with the description: | Overview: 10. The scheme that is the subject of this Ruling involves the merger of Sylvastate with Whitefield. | Sylvastate: 11. Sylvastate was founded in 1924 and, at the time of the scheme, was an Australian resident company listed on the Australian Securities Exchange (ASX). It was an investment company with significant holdings in shares in other listed companies. As at 31 December 2010, Sylvastate's investment portfolio represented 91% of Sylvastate's total assets. Approximately 19.89% of that investment portfolio was made up of shares in Whitefield. 12. Sylvastate had, at the time of the scheme, 15,798,150 fully paid ordinary shares on issue. Each ordinary share carried the same rights to vote, receive dividends and receive capital. 13. Sylvastate did not have any other class of shares on issue. | Whitefield: 14. Whitefield is an Australian resident company listed on the ASX. It is an investment company which holds a large portfolio of shares in listed companies (including a small number of shares in Sylvastate at the time of the scheme). 15. Whitefield is not a member of a wholly-owned group as defined in section 975-500. | The scheme: 16. On 6 July 2010, Sylvastate and Whitefield announced their intention to pursue a merger of the two companies. 17. Following this initial announcement, Sylvastate and Whitefield entered into a merger implementation agreement on 14 February 2011, under which it was agreed that the proposed merger, which would involve the transfer of all Sylvastate shares (other than those already held by Whitefield) to Whitefield, would be implemented by way of a Scheme of Arrangement under Part 5.1 of the Corporations Act 2001 . 18. On 15 April 2011, a court ordered scheme meeting of Sylvastate shareholders was held and a resolution passed by the requisite majority of Sylvastate shareholders approving the proposed scheme of arrangement. 19. On 10 May 2011, the scheme was implemented (the Implementation Date). As a result of the scheme, Sylvastate became a wholly-owned subsidiary of Whitefield. | The scheme consideration: 20. In consideration for the transfer of their shares to Whitefield, Sylvastate shareholders, other than Whitefield and ineligible overseas shareholders, who held Sylvastate shares on the record date for the scheme of 7pm on 6 May 2011 (Record Date), received shares in Whitefield. 21. The number of Whitefield shares issued to each eligible Sylvastate shareholder was determined by the following formula: 22. Based on this formula, an eligible Sylvastate shareholder was entitled to receive 1.15467 shares in Whitefield for each Sylvastate share that they held on the scheme Record Date. 23. Fractional entitlements to Whitefield shares were rounded up or down to the nearest whole number of Whitefield shares, after aggregating all holdings of the relevant shareholder. An entitlement to half a Whitefield share was rounded up. | Ineligible overseas shareholders: 24. Certain foreign shareholders (Ineligible Overseas Shareholders) were not entitled to receive Whitefield shares under the scheme. Instead, the Whitefield shares that would otherwise have been issued to those shareholders were issued to, and held by, a nominee. The nominee then sold the Whitefield shares on the ASX and paid the cash proceeds to the Ineligible Overseas Shareholders. | Sylvastate's interim dividend: 25. Sylvastate declared an interim dividend of $0.105 per share on 24 March 2011. This dividend was paid to entities who were Sylvastate shareholders on the relevant record date 11 April 2011. It represented the ordinary interim dividend payable by Sylvastate in respect of the six month period ended 28 February 2011 and its payment was not conditional on the scheme being approved or implemented. | Other matters: 26. For the purposes of subsections 124-780(4) and 124-780(5), no original interest holder in Sylvastate was, just before the relevant arrangement started, a member of a linked group which includes Sylvastate and Whitefield. 27. There are no 'significant stakeholders' or 'common stakeholders' in relation to the Scheme within the meaning of those expressions in section 124-783. 28. Just before the arrangement started, both Sylvastate and Whitefield had at least 300 members and did not have concentrated ownership of the nature described in section 124-810. | CGT event A1 happened on the disposal of Sylvastate shares to Whitefield: 29. CGT event A1 happened as a result of the disposal by a Sylvastate shareholder of their Sylvastate shares to Whitefield under the scheme described in this Ruling (subsections 104-10(1) and (2)). 30. The time of the event was when the Sylvastate shares were transferred to Whitefield on the Implementation Date of the scheme (paragraph 104-10(3)(b)). | Capital gain or capital loss: 31. A Sylvastate shareholder made a capital gain when CGT event A1 happened if the capital proceeds from the disposal of each Sylvastate share exceeded its cost base. A Sylvastate shareholder made a capital loss if the capital proceeds were less than the reduced cost base of the Sylvastate share (subsection 104-10(4)). | Capital proceeds: 32. The capital proceeds from the disposal of each Sylvastate share are the market value of the Whitefield shares received (worked out as at the time that CGT event A1 happened) that is reasonably attributable to the disposal of the Sylvastate share (subsections 116-20(1) and 116-40(1)). 33. In working out the market value of the Whitefield shares received that is reasonably attributable to the disposal of each Sylvastate share, the Commissioner accepts the following formula: Market value of Whitefield share x ( Total number of Whitefield shares received / Total number of Sylvastate shares exchanged for Whitefield shares ) 34. The Commissioner accepts that the amount of $3.34178 (Whitefield's adjusted NAB on a per share basis on the Implementation Date) is indicative of the market value of a Whitefield share on the Implementation Date of the scheme. 35. The capital proceeds from the disposal of each Sylvastate share to Whitefield under the scheme does not include the interim dividend of $0.105 per share received by a Sylvastate shareholder. | Scrip for scrip roll-over: 36. Subject to the qualification in paragraph 37 of this Ruling, a Sylvastate shareholder who made a capital gain from the disposal of a Sylvastate share to Whitefield is eligible to choose scrip for scrip roll-over (section 124-780 and subsection 124-785(1)). 37. Scrip for scrip roll-over cannot be chosen if any capital gain the Sylvastate shareholder made from the replacement Whitefield shares would be disregarded, except because of a roll-over (paragraph 124-795(2)(a)). 38. The only capital proceeds received by a Sylvastate shareholder were shares in Whitefield. Therefore, if a Sylvastate shareholder chooses scrip for scrip roll-over, the capital gain they made upon the disposal of a Sylvastate share to Whitefield is disregarded completely (subsection 124-785(1)). | Discount capital gain: 39. A Sylvastate shareholder who made a capital gain where roll-over is not chosen, or cannot be chosen, can treat the capital gain as a 'discount capital gain' provided that the conditions in Subdivisions 115-A and, if applicable, 115-C are satisfied. | Cost base of Whitefield shares: 40. The method for calculating a Sylvastate shareholder's cost base and reduced cost base of the Whitefield shares received under the scheme depends on whether the shareholder chooses scrip for scrip roll-over. | Scrip for scrip roll-over is not chosen: 41. Where scrip for scrip roll-over is not chosen, or cannot be chosen, the first element of the Sylvastate shareholder's cost base and reduced cost base of each Whitefield share is equal to the market value of the part of the Sylvastate shares that is reasonably attributable to the acquisition of the Whitefield share, worked out as at the time of their acquisition on the Implementation Date (subsections 110-25(2), 110-55(2) and section 112-30). 42. The Commissioner accepts that the amount of $3.86854 (Sylvastate's adjusted NAB on a per share basis on the Implementation Date) is indicative of the market value of each Sylvastate share given in exchange for the Whitefield shares. | Scrip for scrip roll-over is chosen: 43. Where scrip for scrip roll-over is chosen, the first element of the cost base and reduced cost base of each Whitefield share is equal to the part of the cost base of the relevant Sylvastate share that is reasonably attributable to the acquisition of the Whitefield share (subsections 124-785(2) and 124-785(4)). | Acquisition date of Whitefield shares: 44. The acquisition date of the Whitefield shares received in exchange for the Sylvastate shares is the date that the shares were issued to the Sylvastate shareholders, being the Implementation Date (item 2 of the table in section 109-10). 45. However, for the purpose of determining whether a capital gain made from any later disposal of their Whitefield shares is eligible to be treated as a 'discount capital gain', Sylvastate shareholders who choose scrip for scrip roll-over are taken to have acquired their Whitefield shares when they acquired the corresponding Sylvastate shares (item 2 of the table in subsection 115-30(1)). | Sylvastate shares acquired before 20 September 1985: 46. Any capital gain or capital loss made on the disposal of a Sylvastate share acquired before 20 September 1985 (pre-CGT Sylvastate share) is disregarded (paragraph 104-10(5)(a)). 47. There is no scrip for scrip roll-over for Sylvastate shares that were acquired before 20 September 1985 (paragraph 124-780(3)(a)). 48. The first element of the cost base (and reduced cost base) for a Whitefield share acquired in exchange for pre-CGT Sylvastate shares is the market value of the replacement Whitefield share just after it was acquired (subsection 124-800(1)). 49. The Commissioner accepts that the amount of $3.34178 (Whitefield's adjusted NAB on a per share basis on the Implementation Date) is indicative of the market value of each replacement Whitefield share just after it was acquired. Commissioner of Taxation 25 May 2011 | Availability of scrip for scrip roll-over: 50. The significant tax consequence that is the subject of this Ruling is the availability of scrip for scrip roll-over under Subdivision 124-M. It enables a shareholder to disregard a capital gain from a share that is disposed of as part of a corporate takeover or merger if the shareholder receives a replacement share in exchange. It also provides special rules for calculating the cost base and reduced cost base of the replacement share. 51. Subdivision 124-M contains a number of conditions for, and exceptions to, a shareholder being eligible to choose scrip for scrip roll-over. The main requirements that are relevant to the scheme that is the subject of this Ruling are: 52. Under the scheme that is the subject of this Ruling, the conditions for roll-over under Subdivision 124-M are satisfied. The Ruling section provides a detailed explanation of the Commissioner's decision in this regard. Therefore, no further explanation is warranted other than the following matters relating to the determination of market value. | Whitefield shares: 53. As noted in this Ruling, it is necessary to determine the market value of Whitefield shares for the purposes of calculating: 54. Generally, a market-based methodology (such as a one day Volume Weighted Average Price on the implementation date of the scheme) is considered to be the most appropriate measure of the market value of a security that is listed on the ASX when determining the CGT consequences arising from a merger under a scheme of arrangement. However in the current circumstances, trading in Whitefield shares is relatively illiquid, which may mean that the share price on the ASX at any particular time may not be reflective of the market value of the shares and is open to manipulation. 55. Whitefield is an investment company. Its assets are largely made up of shares in companies listed on the ASX and cash or cash equivalents. Given these attributes, the Commissioner accepts that a market valuation that is based on the adjusted NAB of Whitefield on the Implementation Date is a more appropriate basis than a market-based methodology for valuing Whitefield shares. On this basis, the Commissioner accepts that the amount of $3.34178 (the adjusted NAB of Whitefield on a per share basis on the Implementation Date) is indicative of: | Sylvastate shares: 56. Where scrip for scrip roll-over is not chosen, or cannot be chosen, the first element of the Sylvastate shareholder's cost base and reduced cost base for each Whitefield share is equal to the market value of the part of the Sylvastate shares that is reasonably attributable to the acquisition of the Whitefield share. The market value is worked out as at the time of the acquisition (subsections 110-25(2), 110-55(2) and section 112-30). 57. The Commissioner accepts that the amount of $3.86854 is indicative of the market value of each Sylvastate share given in exchange for the Whitefield shares. This value is based on the adjusted NAB of Sylvastate on a per share basis on the Implementation Date which, for reasons similar to those noted in paragraphs 54 and 55 of this Ruling, is considered to be an appropriate basis for valuing the shares in Sylvastate. 58. The following is a detailed contents list for this Ruling: Not previously issued as a draft

Ruling: CGT event A1 happened on the disposal of Sylvastate shares to Whitefield: 29. CGT event A1 happened as a result of the disposal by a Sylvastate shareholder of their Sylvastate shares to Whitefield under the scheme described in this Ruling (subsections 104-10(1) and (2)). 30. The time of the event was when the Sylvastate shares were transferred to Whitefield on the Implementation Date of the scheme (paragraph 104-10(3)(b)). | Capital gain or capital loss: 31. A Sylvastate shareholder made a capital gain when CGT event A1 happened if the capital proceeds from the disposal of each Sylvastate share exceeded its cost base. A Sylvastate shareholder made a capital loss if the capital proceeds were less than the reduced cost base of the Sylvastate share (subsection 104-10(4)). | Capital proceeds: 32. The capital proceeds from the disposal of each Sylvastate share are the market value of the Whitefield shares received (worked out as at the time that CGT event A1 happened) that is reasonably attributable to the disposal of the Sylvastate share (subsections 116-20(1) and 116-40(1)). 33. In working out the market value of the Whitefield shares received that is reasonably attributable to the disposal of each Sylvastate share, the Commissioner accepts the following formula: Market value of Whitefield share x ( Total number of Whitefield shares received / Total number of Sylvastate shares exchanged for Whitefield shares ) 34. The Commissioner accepts that the amount of $3.34178 (Whitefield's adjusted NAB on a per share basis on the Implementation Date) is indicative of the market value of a Whitefield share on the Implementation Date of the scheme. 35. The capital proceeds from the disposal of each Sylvastate share to Whitefield under the scheme does not include the interim dividend of $0.105 per share received by a Sylvastate shareholder. | Scrip for scrip roll-over: 36. Subject to the qualification in paragraph 37 of this Ruling, a Sylvastate shareholder who made a capital gain from the disposal of a Sylvastate share to Whitefield is eligible to choose scrip for scrip roll-over (section 124-780 and subsection 124-785(1)). 37. Scrip for scrip roll-over cannot be chosen if any capital gain the Sylvastate shareholder made from the replacement Whitefield shares would be disregarded, except because of a roll-over (paragraph 124-795(2)(a)). 38. The only capital proceeds received by a Sylvastate shareholder were shares in Whitefield. Therefore, if a Sylvastate shareholder chooses scrip for scrip roll-over, the capital gain they made upon the disposal of a Sylvastate share to Whitefield is disregarded completely (subsection 124-785(1)). | Discount capital gain: 39. A Sylvastate shareholder who made a capital gain where roll-over is not chosen, or cannot be chosen, can treat the capital gain as a 'discount capital gain' provided that the conditions in Subdivisions 115-A and, if applicable, 115-C are satisfied. | Cost base of Whitefield shares: 40. The method for calculating a Sylvastate shareholder's cost base and reduced cost base of the Whitefield shares received under the scheme depends on whether the shareholder chooses scrip for scrip roll-over. | Scrip for scrip roll-over is not chosen: 41. Where scrip for scrip roll-over is not chosen, or cannot be chosen, the first element of the Sylvastate shareholder's cost base and reduced cost base of each Whitefield share is equal to the market value of the part of the Sylvastate shares that is reasonably attributable to the acquisition of the Whitefield share, worked out as at the time of their acquisition on the Implementation Date (subsections 110-25(2), 110-55(2) and section 112-30). 42. The Commissioner accepts that the amount of $3.86854 (Sylvastate's adjusted NAB on a per share basis on the Implementation Date) is indicative of the market value of each Sylvastate share given in exchange for the Whitefield shares. | Scrip for scrip roll-over is chosen: 43. Where scrip for scrip roll-over is chosen, the first element of the cost base and reduced cost base of each Whitefield share is equal to the part of the cost base of the relevant Sylvastate share that is reasonably attributable to the acquisition of the Whitefield share (subsections 124-785(2) and 124-785(4)). | Acquisition date of Whitefield shares: 44. The acquisition date of the Whitefield shares received in exchange for the Sylvastate shares is the date that the shares were issued to the Sylvastate shareholders, being the Implementation Date (item 2 of the table in section 109-10). 45. However, for the purpose of determining whether a capital gain made from any later disposal of their Whitefield shares is eligible to be treated as a 'discount capital gain', Sylvastate shareholders who choose scrip for scrip roll-over are taken to have acquired their Whitefield shares when they acquired the corresponding Sylvastate shares (item 2 of the table in subsection 115-30(1)). | Sylvastate shares acquired before 20 September 1985: 46. Any capital gain or capital loss made on the disposal of a Sylvastate share acquired before 20 September 1985 (pre-CGT Sylvastate share) is disregarded (paragraph 104-10(5)(a)). 47. There is no scrip for scrip roll-over for Sylvastate shares that were acquired before 20 September 1985 (paragraph 124-780(3)(a)). 48. The first element of the cost base (and reduced cost base) for a Whitefield share acquired in exchange for pre-CGT Sylvastate shares is the market value of the replacement Whitefield share just after it was acquired (subsection 124-800(1)). 49. The Commissioner accepts that the amount of $3.34178 (Whitefield's adjusted NAB on a per share basis on the Implementation Date) is indicative of the market value of each replacement Whitefield share just after it was acquired. Commissioner of Taxation 25 May 2011


Appendix: Availability of scrip for scrip roll-over: 50. The significant tax consequence that is the subject of this Ruling is the availability of scrip for scrip roll-over under Subdivision 124-M. It enables a shareholder to disregard a capital gain from a share that is disposed of as part of a corporate takeover or merger if the shareholder receives a replacement share in exchange. It also provides special rules for calculating the cost base and reduced cost base of the replacement share. 51. Subdivision 124-M contains a number of conditions for, and exceptions to, a shareholder being eligible to choose scrip for scrip roll-over. The main requirements that are relevant to the scheme that is the subject of this Ruling are: 52. Under the scheme that is the subject of this Ruling, the conditions for roll-over under Subdivision 124-M are satisfied. The Ruling section provides a detailed explanation of the Commissioner's decision in this regard. Therefore, no further explanation is warranted other than the following matters relating to the determination of market value. | Whitefield shares: 53. As noted in this Ruling, it is necessary to determine the market value of Whitefield shares for the purposes of calculating: 54. Generally, a market-based methodology (such as a one day Volume Weighted Average Price on the implementation date of the scheme) is considered to be the most appropriate measure of the market value of a security that is listed on the ASX when determining the CGT consequences arising from a merger under a scheme of arrangement. However in the current circumstances, trading in Whitefield shares is relatively illiquid, which may mean that the share price on the ASX at any particular time may not be reflective of the market value of the shares and is open to manipulation. 55. Whitefield is an investment company. Its assets are largely made up of shares in companies listed on the ASX and cash or cash equivalents. Given these attributes, the Commissioner accepts that a market valuation that is based on the adjusted NAB of Whitefield on the Implementation Date is a more appropriate basis than a market-based methodology for valuing Whitefield shares. On this basis, the Commissioner accepts that the amount of $3.34178 (the adjusted NAB of Whitefield on a per share basis on the Implementation Date) is indicative of: | Sylvastate shares: 56. Where scrip for scrip roll-over is not chosen, or cannot be chosen, the first element of the Sylvastate shareholder's cost base and reduced cost base for each Whitefield share is equal to the market value of the part of the Sylvastate shares that is reasonably attributable to the acquisition of the Whitefield share. The market value is worked out as at the time of the acquisition (subsections 110-25(2), 110-55(2) and section 112-30). 57. The Commissioner accepts that the amount of $3.86854 is indicative of the market value of each Sylvastate share given in exchange for the Whitefield shares. This value is based on the adjusted NAB of Sylvastate on a per share basis on the Implementation Date which, for reasons similar to those noted in paragraphs 54 and 55 of this Ruling, is considered to be an appropriate basis for valuing the shares in Sylvastate.


What this Ruling is about | NOT LEGALLY BINDING SECTION: | A public ruling is an expression of the Commissioner's opinion about the way in which a relevant provision applies, or would apply, to entities generally or to a class of entities in relation to a particular scheme or a class of schemes. | If you rely on this ruling, the Commissioner must apply the law to you in the way set out in the ruling (unless the Commissioner is satisfied that the ruling is incorrect and disadvantages you, in which case the law may be applied to you in a way that is more favourable for you - provided the Commissioner is not prevented from doing so by a time limit imposed by the law). You will be protected from having to pay any underpaid tax, penalty or interest in respect of the matters covered by this ruling if it turns out that it does not correctly state how the relevant provision applies to you. | CS was the number of Whitefield shares issued to the relevant Sylvastate shareholder under the scheme; | SS was the number of Sylvastate shares held by the relevant Sylvastate shareholder as at the scheme Record Date; | Sylvastate Adjusted Net Asset Backing (NAB ) was the NAB of Sylvastate as at 31 March 2011, adjusted to reflect Sylvastate's investment in Whitefield being valued on the basis of the NAB per Whitefield share, less residual scheme costs and Sylvastate's interim dividend; | Whitefield Adjusted NAB was the NAB of Whitefield as at 31 March 2011, adjusted to reflect Whitefield's investment in Sylvastate being valued on the basis of the NAB per Sylvastate share, less the face value of Whitefield's issued preference shares, residual scheme costs and Whitefield's final dividends; | NAB was the NAB for accounting purposes, which takes into account a deduction for future tax liabilities that would be incurred in the event the entire portfolio was realised at the date on which the asset backing is determined, and which also takes into account as an asset any future tax benefit from tax losses; and | Calculation Date means 31 March 2011. | Disposal of shares in Sylvastate | If a capital gain was made | Calculating the market value of Whitefield and Sylvastate shares | Appendix 2 - Detailed contents list


Related rulings: TR 2006/10
Legislative references: ITAA 1936 6(1) ITAA 1997 ITAA 1997 104-10(1) ITAA 1997 104-10(2) ITAA 1997 104-10(3)(b) ITAA 1997 104-10(4) ITAA 1997 104-10(5)(a) ITAA 1997 109-10 ITAA 1997 110-25 ITAA 1997 110-25(2) ITAA 1997 110-55 ITAA 1997 110-55(2) ITAA 1997 112-30 ITAA 1997 Subdiv 115-A ITAA 1997 115-30 ITAA 1997 115-30(1) ITAA 1997 Subdiv 115-C ITAA 1997 116-20 ITAA 1997 116-20(1) ITAA 1997 116-40(1) ITAA 1997 Subdiv 124-M ITAA 1997 124-780 ITAA 1997 124-780(3)(a) ITAA 1997 124-780(4) ITAA 1997 124-780(5) ITAA 1997 124-783 ITAA 1997 124-785(1) ITAA 1997 124-785(2) ITAA 1997 124-785(4) ITAA 1997 124-795(2)(a) ITAA 1997 124-800(1) ITAA 1997 124-810 ITAA 1997 975-500 Corporations Act 2001 Pt 5.1 TAA 1953 Copyright Act 1968
Subject references: arrangement arrangement capital gains CGT event A1- disposal of a CGT asset Disposal of assets Exchange of shares CGT roll-over relief Disposal of Shares